Tempus Q3 2026 Financial Results Call - TEMPUS AI INC

Financial Performance:

• Total revenue reached $411.5 million in Q3 2026, representing a 23% year-over-year increase.
• Diagnostics segment generated $303.5 million (+20% YoY), with oncology at $172.6 million (+28%) and hereditary cancer testing at $111.3 million; oncology unit volume grew 32%.
• Data and applications segment generated $108.1 million (+33% YoY), led by Insights licensing which grew 29%.
• Achieved positive adjusted EBITDA of $25.6 million for the quarter, marking a strategic inflection point.
• Ended the quarter with $854.4 million in cash and marketable securities.
• Oncology Average Selling Price (ASP) expected to increase by approximately $80 million in 2027 due to updated FDA pricing and reimbursement rates.

Guidance and Future Outlook:

• Raised full-year 2026 revenue guidance to $1.60 billion – $1.605 billion.
• Maintained 2026 adjusted EBITDA guidance of approximately $65 million.
• Management targets a long-term sustainable growth rate of ~25% annually, prioritizing durability over short-term spikes.
• Anticipates significant ASP uplift in oncology early in 2027, with further increases expected upon final FDA approval for the XF assay.
• Data and applications business forecast to continue outperforming with strong visibility through multi-year strategic collaborations.

Business Segments and Product Lines:

• Oncology: Driving growth via solid tumor profiling (CGP) and liquid biopsy; solid tumor portfolio growing ~32% on units.
• Hereditary Cancer: Growth rates moderating from exceptional highs to a more stable trajectory, lapping the previous year's anomaly; rare disease segment growing to offset PAMA cut risks.
• MRD (Minimal Residual Disease): Currently ramping at 3,000 units/quarter with only 15% of sales force dedicated; expects full commercial unlock post-acquisition of Personalis once unit economics turn positive (targeted for mid-2027).
• Data & AI: Launched strategic collaborations with Bristol-Myers Squibb ($137.5M over 5 years) and BMS/Pathos for Alzheimer's data ($55M over 5 years), totaling $192.5M in future revenue.
• Personalis Acquisition: Regulatory review cleared; shareholder meeting scheduled for November 30, 2026. Integration aims to add best-in-class NEXT assay to the multimodal portfolio.

Market and Competitive Landscape:

• Tempest holds #1 or #2 market position in solid tumor profiling, liquid biopsy, and hereditary cancer profiling, with projections to join this tier in MRD.
• Competitor landscape includes Foundation Medicine, Natera, and Guardant; Tempest differentiates via a "best-in-class" technology stack and deep integration with 8,000+ providers.
• Market trend toward concurrent testing (solid tumor + liquid) is driving liquid biopsy volume, potentially outpacing solid tumor growth in Q4.
• Data business transitioning from episodic licensing to sticky, long-term enterprise subscriptions with integrated AI modeling capabilities.

Risks and Challenges:

• PAMA reimbursement cuts present a minor headwind for hereditary cancer ASPs, though offset by growth in the rare disease portfolio.
• Personalis acquisition currently carries a loss profile; earnings impact must be absorbed by Tempest until Personalis achieves positive per-test gross profit.
• Market risks include potential fluctuations in clinical trial matching demand due to AI disruption in CRO administrative functions.
• Reliance on reimbursement landscape evolution for new diagnostic categories (e.g., cardiology, immunology).

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing the "turning of the corner" on profitability and the durability of the business model.
• Management highlighted the strategic moat built on 600+ petabytes of data and the "flywheel" effect of combining diagnostics with AI insights.
• Executive leadership expressed strong belief in the synergies of the Personalis acquisition and the transformative potential of AI in healthcare.
• CEO Eric Lepkovsky and CFO Jim Rogers emphasized the company's transition from a pure tech investment to a cash-generating entity with reinvestment discipline (2/3 gross profit to reinvestment, 1/3 to EBITDA).

Analyst Questions and Answers:

• Hereditary & ASPs: Clarified that PAMA cuts will have minimal impact due to the mix shift toward rare diseases; significant ASP tailwinds expected in oncology starting 2027.
• Long-term Growth: Confirmed 25% CAGR is the sustainable target; short-term spikes possible due to ASPs and data growth, but long-term compounding is the focus.
• MRD Rollout: Full sales force deployment for Personalis MRD expected mid-2027, contingent on achieving positive unit economics and reimbursement for additional indications (e.g., colorectal).
• Data Stickiness: New AI modeling environment (Lens + private GPU clusters) creates high switching costs; customers now building models in-platform rather than downloading raw data.
• EBITDA Trajectory: Reinvestment rate of ~66% of incremental gross profit will continue until Personalis is fully integrated and profitable; EBITDA margin expected to expand significantly thereafter.

Other Key Points:

• Strategic collaborations with AstraZeneca, Merck, GSK, BioNTech, and now BMS solidify the data moat.
• The company has amassed over 50 petabytes of new data in the last quarter, bringing the total to 600+ petabytes.
• Clinical trial matching business (TIME) pivoted from a marketplace to an enterprise-focused, high-margin service for large pharma partners, though not expected to reach billion-dollar scale.
• Over 80% of the current patient dataset is non-oncology, diversifying data sources beyond the core cancer business.
• Retail investors via Robinhood were able to submit questions, which were answered regarding non-oncology growth potential and data liquidity risks.